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Background. Nephroblastoma is one of the most common childhood malignancies in Africa, but with a survival rate significantly lower 
than in developed countries. In African countries with a small gross domestic product (GDP) per capita, the cost of treating nephroblastoma 
may be prohibitive. 
Objectives. To determine the direct costs of treatment of nephroblastoma in South Africa (SA) and to propose a more cost-effective 
approach to investigations and treatment for the disease in Africa.
Methods. Data from 2000 to 2010 from two SA paediatric oncology units were retrospectively analysed. The costs included investigations, 
chemotherapy and radiotherapy, comparing early- v. advanced-stage disease. In both units, the nephroblastoma International Society of 
Paediatric Oncology (SIOP) protocol was used.
Results. Stage I disease was the most common, followed by stage IV. The total cost of diagnosis, staging and treatment of stage I disease 
was ZAR9 304.97 (EUR882.80 or USD1 093.40), compared with a five-times higher cost for stage IV (ZAR48 293.62 (EUR4 581.9 or 
USD5 674.9)). Treating one patient averted more than 32 disability-adjusted life years. The investigation and treatment of early- and 
advanced-stage disease is very cost-effective when compared with the local GDP per capita. 
Conclusion. The cost of investigation and treatment of nephroblastoma remains a challenge everywhere, but especially in Africa. However, 
it is a very cost-effective disease to treat and children in Africa should not be denied treatment.
S Afr J CH 2014;8(4):128-132. DOI:10.7196/SAJCH.749 
Nephroblastoma or Wilms’ tumour is one of the 
most common childhood cancers in Africa. It 
represents ~6 - 7% of childhood cancers in high-
income countries,[1] but up to 26% in some African 
countries. [2] In First-World countries, it has a high 
cure rate of >90% when treated with chemotherapy, surgery and 
radiotherapy, compared with disappointing results in low-income 
countries.[3,4] There are currently no data on the costs of treating 
nephroblastoma in children in Africa. On a continent where gross 
domestic product (GDP) figures per capita, excluding South Africa 
(SA), rarely exceeds USD2 000 (United States Dollar), and in many 
countries in fact is less than USD1 000,[5] the expenditure incurred 
by the standard management of this disease in children may be 
unaffordable. 
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This study proposed to estimate the cost of managing nephro-
blastoma, based on data available from two paediatric oncology units 
(POUs) based in Cape Town and Bloemfontein, and to critically 
evaluate the various cost contributors in order to find ways of 
reducing the cost of treatment without compromising remission 
or survival rates. The specific objectives of the study were to: 
determine the total number of children diagnosed and treated for 
nephroblastoma between 2000 and 2010 in the two POUs; correlate 
the stage of disease with survival; quantify the resources used in the 
diagnosis, staging and treatment; compare the costs of treating a 
patient with an early-stage nephroblastoma (stage I) with a patient 
with metastatic disease (stage IV); and propose a more cost-effective 
approach to investigation and treatment for children diagnosed with 
nephroblastoma in Africa.
Methods
Patients aged 0 - 15 years, diagnosed with nephroblastoma between 
2000  and  2010 at Tygerberg Hospital (TBH) in Cape Town and 
Universitas Hospital Academic Complex (UHAC) in Bloemfontein, 
were included in the study. TBH is a tertiary referral hospital located 
in Parow, Cape Town, serving the eastern metropolitan region of 
Cape Town and the north-eastern districts of the Western Cape 
Province. The hospital, being the largest hospital in the Western 
Cape and the second largest hospital in SA, provides healthcare to 
2.4 million children. This POU admits an average of 50 - 60 new 
patients per year.
The UHAC is situated in Bloemfontein and provides cancer care 
to patients in central SA, and is the referral POU for the whole of the 
Free State and Northern Cape Provinces, Lesotho, as well as for some 
areas of the North West and Eastern Cape Provinces. The unit sees 
~100 new oncology patients per year.
The treatment protocol used in both units for the treatment 
of nephroblastoma was the International Society of Paediatric 
Oncology (SIOP) 1987, followed by SIOP 2001.[6] The SIOP protocol 
is based on the administration of preoperative chemotherapy prior 
to the surgical resection. The National Health Laboratory Service 
confirmed the histological diagnosis in all cases where a surgical 
resection was performed. Some patients who died before surgical 
excision were diagnosed clinically or on typical radiological find-
ings. Radiotherapy included flank and pulmonary irradiation.
Staging tests were performed initially in order to make the 
diagnosis and to establish whether there was metastatic disease 
or bilateral disease. An abdominal ultrasound was followed by a 
computed tomography (CT) scan of the abdomen and, in many 
cases, by a fine-needle aspiration. Chest radiography (CXR) was 
part of the initial assessment and was complemented by a CT scan 
of the chest, mostly in cases with suspected pulmonary metastases. 
Magnetic resonance imaging (MRI) of the abdomen was occasionally 
performed on request of the surgeons, to assist in planning the 
surgery and also at one of centres based on the choice of the 
radiology department, owing to less radiation exposure. Patients 
who were not staged included those who died soon after admission 
or failed to proceed to surgery. 
The costs of staging investigations as well as the cost of treatment 
were obtained from the various hospital departments involved, i.e. 
pharmacy, radiology, radiotherapy and laboratory, at 2012 tariffs. 
The cost of all investigations is the same at all SA government 
institutions. Patients <6 years old receive all investigations and 
treatment free of charge. Patients >6 years old are categorised 
according to the parents’ monthly income, and the family has to pay 
a percentage of the total cost depending on the category. Patients 
>6 years of age who receive a care dependency grant from the 
government are also exempt from all cost. 
This analysis excluded the expenditure incurred for hospitalisa-
tion, dispensable stock used (e.g. syringes, needles, drip sets, etc.), 
and surgical and theatre costs. The costs presented were based on 
the calculation of expenses as for the stage I intermediate group as 
the most common in our group, and the stage IV group as possibly 
the most expensive treatment. The currency used was the SA Rand 
(ZAR). Conversions to the USD and Euro (EUR) were made at 
the 2012 exchange rate at the time when all costs were determined 
(1USD = ZAR8.51; 1EUR = ZAR10.54). 
To calculate the mortality and morbidity effect of nephroblastoma 
on the population, disability-adjusted life years (DALYs) were 
calculated. The cost-effectiveness of the relevant investigations and 
treatment described were determined according to the World Health 
Organization (WHO) CHOICE guideline. The CHOICE (CHOosing 
Interventions that are Cost-Effective) project is a WHO initiative 
developed in 1998 with the objective of providing policy makers 
with evidence for deciding on interventions and programmes that 
maximise health for the available resources. 
To quantify the mortality and morbidity effect that a disease has 
on a population, DALYs needed to be calculated. One DALY is a year 
of healthy life that is lost due to the disease. The number of DALYs 
in a specific population is an indication of the state of healthcare in 
that population. The more DALYs lost in a country, the poorer the 
Table 1. Summary of chemotherapy regimens for stage I intermediate risk and stage IV arm B (SIOP)
Stage Phase Stage Drug Schedule
I Preoperative Localised disease Actinomycin D 45 µg/kg Weeks 1 and 3
Vincristine 1.5 mg/m2 Weeks 1 - 4
Postoperative Stage I intermediate risk Actinomycin D 45 µg/kg Week 2
Vincristine 1.5 mg/m2 Weeks 1 - 4
IV Preoperative Metastatic disease Actinomycin D 45 µg/kg Weeks 1, 3, 5
Vincristine 1.5 mg/m2 Weeks 1 - 6
Doxorubicin 50 mg/m2 Weeks 1, 5
Postoperative Stage IV arm B Etoposide 150 mg/m2 Days 1 - 3 in weeks 4, 10, 13, 16, 22, 25, 28, 34
Carboplatin 200 mg/m2 Days 1 - 3 in weeks 4, 10, 13, 16, 22, 25, 28, 34
Cyclophosphamide 
450 mg/m2
Days 1 - 3 in weeks 1, 7, 19, 31
Doxorubicin 50 mg/m2 Day 1 in weeks 1, 7, 19, 31
SIOP = International Society of Paediatric Oncology.
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national health situation. The WHO definition of DALYs is the sum 
of years of potential life lost (YLL) due to premature mortality and the 
years of productive life lost due to disability (YLD). To calculate the 
YLL, we subtracted the average age of death (2 years) from the SA life 
expectancy (59.55 years).[7] To calculate the annual estimated number 
of life years lost due to early death if no treatment was provided, the 
difference was multiplied by the annual number of nephroblastoma 
cases in SA (61 per year in 2007).[8] The total number was 3 388.6 years. 
The total YLD was calculated by multiplying the disability weight of 
nephroblastoma (0.09)[9] with the estimated duration of illness with 
or without treatment (1 year). The Global Burden of Disease working 
group has determined disability weights of various diseases. A score of 
1 indicates perfect health and 0 indicates death. 
Ethics approval
Ethics approval was obtained from the relevant human ethics research 
committees of the two participating centres. Patient confidentiality 
was maintained by using de-identified data.
Results 
There were 146 patients diagnosed between the two units: 75 males 
and 71 females (male/female ratio 1.06:1 with an equal distribution 
between the two units. The median age was 39 (range 3 - 167) 
months. At diagnosis, there were 99 cases with localised disease, 
of which 6 were bilateral, 36 had metastatic disease and 5 patients 
did not have staging investigations. The most common stages post 
surgery were stage 1 (50%) and stage IV (23%). Stages II and III had 
a similar incidence of about 10%. Stage V (bilateral) was seen in only 
4% of patients. There were five children in whom the stage was not 
performed or it was unknown. We classified stages I and II as early 
disease and stages III and IV as late stage (more advanced disease) 
for practical reasons. Despite the fact that the treatment protocols of 
stages III and IV are not the same, both stages deal with advanced 
disease and a more reserved survival rate.
Overall, 78.3% of patients with early-stage disease survived, while 
only 47.3% of patients with advanced-stage disease survived. 
The cost of various tests, procedures and chemotherapy were 
divided into early-stage (of which stage I intermediate risk formed 
the largest part) and v. advanced-stage disease, represented by stage 
IV disease, which received the most intensive treatment (Table 2). The 
cost of each stage was calculated first by utilising MRI for diagnosis 
and then without MRI.
The costs of investigations included full blood and differential 
counts and electrolytes (renal function), both tested 10 times for 
Table 2. Costs of investigations, procedures and treatment used in patients with nephroblastoma*
Stage I intermediate risk Stage IV SIOP arm B
Imaging modality used CT abdomen MRI abdomen
CT abdomen, 
2 × CT chest
MRI abdomen, 
2 × CT chest
Histology: processing histology block, H&E stain 200.00 200.00 200.00 200.00
Cytology: FNA 4 slides, Papanicolaou and Giemsa stains 785.36 785.36 785.36 785.36
Full blood and differential count (R27.54)† 275.40 (× 10) 275.40 (× 10) 523.26 (× 19) 523.26 (× 19)
Urea and electrolytes (R73.83)‡ 738.30 (× 10) 738.30 (× 10) 1 402.77 (× 19) 1 402.77 (× 19)
Liver function (× 2) (× 2) (× 3) (× 3)
EBV serology 97.43 97.43 97.43 97.43
CMV serology 97.43 97.43 97.43 97.43
Hepatitis A, B and C tests 327.00 327.00 327.00 327.00
HIV ELISA 47.77 47.77 47.77 47.77
Mantoux 141.00 141.00 141.00 141.00
CXR AP and lateral 150.00 150.00 150.00 150.00
CT chest with anaesthetic 2 166.00 2 166.00 2 166.00 2 166.00
CT abdomen with anaesthetic 2 166.00 - 2 166.00 -
Abdominal ultrasound × 2 300.00 300.00 300.00 300.00
Echo - - 150.00 150.00
MRI abdomen with anaesthetic - 6 826.00 - 6 826.00
Chemotherapy 1 813.28 1 813.28 6 748.92 6 748.92
Radiotherapy: flank/pulmonary - - 26 460.00 26 460.00
Total ZAR9 304.97
EUR882.8
USD1 093.4
ZAR13 964.97
EUR1 324.9
USD1 641
ZAR41 762.94
EUR3 92.32
USD4 907.51
ZAR46 422.94
EUR4 404.45
USD5 455.10
SIOP = International Society of Paediatric Oncology; CT = computed tomography; MRI = magnetic resonance imaging; H&E = haematoxilyn and eosin;  
FNA = fine-needle aspiration; EBV = Epstein-Barr virus; CMV = cytomegalovirus; ELISA = enzyme-linked immunosorbent assay; CXR = chest radiography;  
AP = anterioposterior.
*Costs obtained from the Department of Health South Africa.
†Full blood and differential counts performed prior to every chemotherapy course, once preoperatively and once postoperatively.
‡Urea and electrolytes were performed twice during the preoperative chemotherapy phase, once preoperatively, once postoperatively and twice during the postoperative phase 
(stage I intermediate risk) or prior to every chemotherapy course (stage IV arm B).
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early stage (prior to every chemotherapy 
course (8), once pre- and postoperatively) 
and 19 times for advanced disease (prior to 
every treatment course (17), as well as once 
pre- and postoperatively).
We also included liver function tests 
(performed at diagnosis and on completion 
of therapy for uncomplicated stage I patients 
and three times for stage IV patients), an 
HIV enzyme-linked immunosorbent assay 
(ELISA) and viral serology (Epstein-Barr, 
cytomegalovirus and hepatitis A, B and C), 
which are routinely performed by the units. 
An echocardiogram was performed to assess 
the initial cardiac function and included at 
the beginning of treatment.
The cost of the chemotherapy was 
calculated taking into consideration a 
typical 3-year-old patient (based on the 
average age at presentation) with a body 
weight of 15 kg and a body surface area of 
0.5  m2. Chemotherapy for stage I patients 
was calculated as for intermediate risk (IR) 
patients, since this was the most common 
risk group, and for stage IV patients receiving 
SIOP stage IV arm B chemotherapy (Table 1). 
The total cost of chemotherapy for a 
stage I IR patient was ZAR1 813.28 (EUR172 
or USD213): the preoperative phase cost 
was estimated at ZAR1  157.40 (EUR109.80 
or USD136) and the postoperative cost 
at ZAR655.80 (EUR62.20 or USD77.10). 
For a stage IV patient, the total cost was 
ZAR6  748.92 (EUR640.30 or USD793.10), 
of which the preoperative phase cost 
ZAR1 876.32 (EUR178 or USD220.50) and 
the postoperative phase cost ZAR4  872.60 
(EUR462.30 or USD572.60).
The number of DALYs lost without 
treatment was 32 (3% discounting).
If a monetary value equal to once the 
GDP was spent on an intervention in order 
to avert 1 DALY, it is considered very cost-
effective. If three or more times the GDP 
was spent to avert 1 DALY, the intervention 
is considered to be cost-effective. SA’s GDP 
per capita is USD7 508,[5] thus treating one 
child with stage I nephroblastoma costs less 
than once the GDP, making the treatment 
very cost-effective. Even treating a child 
with stage IV nephroblastoma is very cost-
effective, since more than 32 DALYs were 
averted by spending only 40% more than 
three times the GDP. 
Discussion
Nephroblastoma is the 4th most common 
childhood malignancy in SA.[8] This 
is the first report analysing the cost of 
treating nephroblastoma in a middle-
income country. This analysis shows 
the difference in the cost of treatment 
between early and advanced disease (5.2-
fold increase). This variation in cost is 
mainly attributed to the more expensive 
postoperative treatment required for stage 
IV, which includes radiotherapy and more 
intensive chemotherapy. Chemotherapy 
for stage I IR disease comprises two drugs 
for 8 weeks, where actinomycin D (ACD) 
boluses are given preoperatively in weeks 1 
and 3 and vincristine (VCR) in weeks 1 - 4; 
postoperatively, ACD is administered in 
week 2 and VCR again in weeks 1 - 4. In 
contrast, stage IV SIOP arm B treatment 
requires six drugs for 34 weeks: in the 
preoperative phase, ACD is given at weeks 1, 
3 and 5, and VCR weekly in weeks 1 - 
6; postoperatively, a patient will receive 
cyclophosphamide and doxorubicin on days 1 
- 3 of weeks 1, 7, 19 and 31, as well as etoposide 
and carboplatin on days 1 - 3 of weeks 4, 10, 
13, 16, 22, 25, 28 and 34. 
Using MRI as a diagnostic modality 
increased the cost of treating a stage I patient 
by R4 660.00 (EUR 754.90 or USD 547.60). 
Lung metastases can be excluded on a 
CXR, since lesions that are not noticeable 
on a CXR do not impact significantly on the 
patient’s prognosis.[10,11] A CT chest in the 
evaluation of response in obvious metastasis 
could be used, and if there is complete 
response to chemotherapy, then pulmonary 
radiation could be avoided, with less cost. 
A search of the literature for the costs 
of treating other childhood cancers found 
that several studies evaluated certain aspects 
of cancer treatment, e.g. use of filgrastim 
or central venous catheters, but very few 
focused on the total direct costs of the 
treatment. A few studies evaluating the cost 
of acute lymphoblastic leukaemia (ALL) 
treatment were found.[12,13] The highest 
cost was reported by Rae et al.,[14] where 
the total cost for the German Berlin-
Frankfurt-Munster ALL protocol ranged 
from USD40  559 to USD255  987 and for 
the American Dana-Farber Cancer Institute 
protocol from USD43 242 to USD262 541. 
Suggestions for cost-effective 
investigation and treatment in a 
resource-limited environment
We suggest limiting the investigations 
for early- and late-stage nephroblastoma 
patients to the following (Table 3): 
stage I patients would need an initial 
diagnostic abdominal ultrasound, and 
it would be prudent to repeat another 
preoperatively. Blood investigations may 
be limited to an ini tial HIV ELISA, full 
blood and differential counts, and renal 
function tests prior to every chemotherapy 
administration (2 during the preoperative 
phase, 1 preoperatively, 1 postoperatively 
and 2 during postoperative phase). Liver 
function tests should be performed twice 
in the preoperative phase: at diagnosis 
and on completion of the phase. Baseline 
hepatitis testing may be performed. In 
countries with a high tuberculosis burden, a 
tuberculin skin test (Mantoux) is necessary 
to help exclude active tuberculosis. Lung 
metastases can be excluded by performing 
one chest radiograph. 
Table 3. Suggested cost-effective investigations, procedures and treatments for patients 
with nephroblastoma in a resource-constrained environment (Africa)
Stage I 
intermediate risk
Stage IV  
SIOP arm B
Histology: processing histology block, H&E stain 200.00 200.00
Full blood count and differential count (R27.54) 165.24 (× 6) 523.26 (× 19)
Urea and electrolytes (R73.83) 442.98 (× 6) 1 402.77 (× 19)
Liver function
Hepatitis tests 327.00 327.00
HIV ELISA 47.77 47.77
Mantoux 141.00 141.00
CXR AP and lateral 150.00 300.00 (× 2)
Abdominal ultrasound 300.00 (× 2) 300.00 (× 2)
CT scan chest with anaesthetic 2 166.00
Echo 150.00
Chemotherapy 1 813.28 6 748.92
Radiotherapy: flank/pulmonary 26 460.00
Total ZAR3 587.27
EUR340.30
USD421.50
ZAR38 766.72
EUR3678.10
USD4 555.40
SIOP = International Society of Paediatric Oncology; H&E = haematoxilyn and eosin; ELISA = enzyme-linked 
immunosorbent assay; CXR = chest radiography; AP = anterioposterior; CT = computed tomography.
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Stage IV patients should have an initial CT scan of the chest to 
better identify the size and location of metastatic lesions. If all lesions 
have disappeared on a follow-up chest radiograph, then a follow-up 
CT scan would be unnecessary. These patients should also have an 
echocardiogram as a safety measure before anthracycline drugs are 
administered. In comparison with a stage I patient who has had 
investigations including CT and MRI scans, as in Table 2, this would 
bring down the cost of the investigation and treatment of stage I 
patients to only ZAR3 587.27 (EUR340.30 or USD421.50) – a 61.4% 
reduction in cost. There would be a 19.7% reduction for comparative 
stage IV patient groups (Table 3). 
Study strengths
This study is the first to conduct an ingredient-based costing analy-
sis, and to determine the specific costs associated with diagnosis and 
treatment of nephroblastoma – one of the most common childhood 
cancers in Africa – using real cost and patient data. The costing 
methodology used ensures ease of replication in different settings and 
transparency of results. Furthermore, results from this study can be 
very useful to inform future cost-effectiveness studies. 
Study weaknesses and challenges
The first limitation is the perspective taken for this costing study, 
i.e. calculating strictly only the costs related to staging, diagnosis, 
investigations and treatment. Wider societal costs, such as out-of-
pocket expenses incurred to patients and their families as a result of 
the illness were not included, as this was beyond the scope of this 
research. This study did not take into consideration the cost of staff 
(salaries) or hospitalisation time due to complications or treatment, 
or the cost of follow-up visits and investigations. Disposables, other 
equipment costs and surgical/theatre costs were also excluded from 
the analysis.
Despite these limitations, this analysis offers policymakers the 
first empirical estimates of the total costs to the health service 
of treating a child with nephroblastoma in two provinces in SA. 
In a country such as SA, with a relatively small GDP per capita 
(USD7 508) and other priorities such as AIDS and TB competing 
for the healthcare budget, the anticipated high costs associated 
with cancer treatment might be a daunting investment. This study 
shows that nephroblastoma is a cost-effective cancer to treat, 
especially when intervening early (when treatment requires less 
intense chemotherapy and no radiotherapy). Therefore, this study 
could be used to educate the population and primary healthcare 
providers on the benefits of early diagnosis and treatment. 
Generalisation must be made with caution though, as this study 
is based on data from two SA units only, which may not reflect 
the costs and treatment regimens in different countries. It could 
nevertheless be useful to raise awareness around childhood cancer 
in the country as well as in other parts of Africa. 
This study could also be used as the start of a more comprehensive 
project involving representatives from all African regions and 
international specialists looking at the cost and cost-effectiveness 
of treating nephroblastoma and other cancers on our continent. In 
November 2013, such a network was formed under the auspices 
of AORTIC (African Organisation for Research and Training in 
Cancer), the African Cancer Economics Network. The objectives 
of this network are, among others, to improve the knowledge about 
the cost of cancer care and cost-effectiveness in Africa. A further 
objective is to play a facilitator role for the advancement of cancer-
related health economics and policymaking capabilities on the 
African continent.
 
Future research
Although this study provides new useful information regarding 
the costs of treating nephroblastoma in SA, these results should be 
incorporated into a full economic evaluation in order to provide a 
better picture of the health benefits and costs of nephroblastoma 
treatment at different stages of the malignancy. 
Conclusion
In high-income countries, the total cost of treatment of 
nephroblastoma is relatively cheap, but in many African countries 
and for numerous patients, treatment remains unaffordable. It is a 
highly curable disease and very cost-effective to treat.
It is essential to increase awareness about childhood cancer, 
specifically nephroblastoma, in order to diagnose children earlier, 
since this will not only reduce costs, but more importantly will lead 
to improved survival rates. 
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